Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H18N3O10.Gd.2H |
Molecular Weight | 547.57 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[Gd+3].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O
InChI
InChIKey=IZOOGPBRAOKZFK-UHFFFAOYSA-K
InChI=1S/C14H23N3O10.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+3/p-3
Molecular Formula | C14H18N3O10 |
Molecular Weight | 388.3068 |
Charge | -5 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H |
Molecular Weight | 1.0079 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Gd |
Molecular Weight | 157.25 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/
Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA that is used in patients undergoing diagnostic contrast-enhanced MRI for visualization of pathological lesions in the CNS and all other body regions or for contrast-enhanced magnetic resonance angiography (MRA) to evaluate perfusion and flow-related abnormalities. It is a non-ionic, paramagnetic complex consisting of gadolinium (Gd3+) chelated with the macrocyclic compound dihydroxy-hydroxymethylpropyl-tetraazacyclododecane-triacetic acid (butrol). Gadavist (the trade name of gadobutrol) was approved by FDA in 2011 for intravenous use in diagnostic MRI in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. Application of gadobutrol in humans, up to a dose of 0.5 mmol/kg was shown to be well tolerated. Following intravenous administration, gadobutrol may increase MRI sensitivity for the detection of tumors and inflammatory and demyelinating diseases of the central nervous system which are associated with areas with blood-brain barrier defects due to altered perfusion or an enlarged extracellular space. Gadobutrol is not metabolized. It is eliminated in an unchanged form via the kidneys; extra-renal elimination is negligible. Side effects include headache, nausea, abnormal taste and feeling hot.
CNS Activity
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf
Curator's Comment: In rats, gadobutrol does not penetrate the intact blood-brain barrier
Originator
Sources: http://www.prnewswire.com/news-releases/fda-approves-dotarem-gadoterate-meglumine-first-macrocyclic-and-ionic-gadolinium-based-contrast-agent-in-usa-199354771.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/7960618
Curator's Comment: # Schering AG (now subsidiary of Bayer)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/31179770 |
105.0 mM [Ki] | ||
Target ID: P52209 Gene ID: 5226.0 Gene Symbol: PGD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20235752 |
73.0 mM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | DOTAREM Approved UseIndicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Launch Date1.36373758E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
|||
Diagnostic | GADAVIST Approved UseGadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease. Launch Date1.30006083E12 |
PubMed
Title | Date | PubMed |
---|---|---|
Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. | 1994 Sep |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. | 2006 Feb |
|
Loss of primary cilia results in deregulated and unabated apical calcium entry in ARPKD collecting duct cells. | 2006 Jun |
|
Gadolinium-based contrast agents and nephrotoxicity. | 2006 Nov |
|
Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data. | 2007 Aug |
|
Large sample of nephrogenic systemic fibrosis cases from a single institution. | 2009 Oct |
|
Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal culture. | 2010 Mar |
|
Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. | 2010 Nov |
|
The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study). | 2015 Sep |
|
MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. | 2016 Mar |
Sample Use Guides
For adult and pediatric patients (2 years and older), the recommended dose of DOTAREM (gadoterate meglumine) is 0.2 mL/kg (0.1 mmol/kg) body weight administered as an intravenous bolus injection, manually or by power injector, at a flow rate of approximately 2 mL/second for adults and 1-2 mL/second for pediatric patients.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:39:56 UTC 2023
by
admin
on
Wed Jul 05 23:39:56 UTC 2023
|
Record UNII |
K2I13DR72L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08CA01
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
||
|
NDF-RT |
N0000180184
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
||
|
NCI_THESAURUS |
C62358
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
||
|
WHO-ATC |
V08CA01
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
||
|
NDF-RT |
N0000175862
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
GADOPENTETIC ACID
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
100000085029
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
C87737
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
M5627
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB00789
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
5396
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200431
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
157429
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
DTXSID701001301
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
80529-93-7
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
SUB07864MIG
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY | |||
|
K2I13DR72L
Created by
admin on Wed Jul 05 23:39:57 UTC 2023 , Edited by admin on Wed Jul 05 23:39:57 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |